STOCK TITAN

Gilead Sciences (GILD) 424B Filings

GILD NASDAQ

Here are the 424B prospectus supplements from Gilead Sciences Inc (GILD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow GILD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GILD filings page.

Rhea-AI Summary

Gilead Sciences, Inc. is conducting a primary offering of senior unsecured notes totaling $3.0 billion across four series: $500 million 4.250% due 2028, $1.0 billion 4.400% due 2029, $1.0 billion 4.600% due 2031 and $500 million 4.900% due 2034. Interest accrues from May 20, 2026 and is payable semiannually on May 20 and November 20, beginning November 20, 2026. Net proceeds are estimated at approximately $2.99 billion and will be used for general corporate purposes, potentially including acquisitions, investments and other strategic uses. The notes are senior unsecured obligations, rank pari passu with other senior unsecured debt and will not be listed on any exchange.

Rhea-AI Summary

Gilead Sciences, Inc. is offering multiple series of senior unsecured notes under a preliminary prospectus supplement related to an effective shelf registration. The notes will be senior unsecured obligations that rank equally with Gilead’s other senior unsecured debt, will be issued in book-entry form through DTC and are payable semiannually commencing in 2026.

The indenture permits optional redemption (including at Par Call Dates) and requires an offer to repurchase the notes at 101% of principal upon a Change of Control Triggering Event. Net proceeds are designated for general corporate purposes. The prospectus supplement incorporates certain SEC filings by reference, including the Form 10-K for the year ended and Form 10-Q for the quarter ended .